Sprycel is launched in Japan

Bristol-Myers Squibb's Sprycel (dasatinib) has been launched in Japan. The multi-targeted tyrosine kinase inhibitor is indicated for the treatment of imatinib-resistant Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML) in the chronic, accelerated or acute (blast) phases, and Ph+ acute lymphoblastic leukaemia (ALL).